Zinc and vitamin B3 supplement for IPF
Treatments studied
Part of Lungs & breathing clinical trials.
This trial tests whether adding zinc and nicotinamide riboside (a vitamin B3-like supplement) to standard IPF treatment can help improve lung function. It is for people with IPF who are already seeing a lung doctor and live in certain states.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be over 50 years old and diagnosed with idiopathic pulmonary fibrosis (IPF) by a lung doctor.
- You must be currently seeing a lung doctor for your IPF and on treatment.
- You must live in one of these states: California, Arizona, Georgia, Louisiana, Minnesota, or Oregon.
- You must be willing to take zinc and nicotinamide riboside (a vitamin B3-like supplement) daily for the study.
- You must be able to do breathing tests, a 6-minute walk, and a CT scan of your chest every 12 to 24 weeks as part of your regular care.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an inhaled form of nintedanib (a drug that helps slow lung scarring) for people with idiopathic pulmonary fibrosis (IPF). It may be an option for those newly diagnosed or already on stable treatment.
This trial tests whether a beetroot juice drink (rich in nitrates) can help people with idiopathic pulmonary fibrosis breathe better and exercise more. It's a small pilot study to see if it's safe and worth studying further.
This trial tests an investigational drug called zampilimab for people with idiopathic pulmonary fibrosis (IPF). It aims to find a safe and effective dose that may slow lung function decline.
This Phase 3 study tests whether adding lansoprazole (a stomach acid medicine) can improve outcomes for people with idiopathic pulmonary fibrosis (IPF). You may already be on IPF “anti-fibrotic” medication, and the study checks if the added lansoprazole helps, compared with placebo.
This trial studies whether adding azithromycin to standard care can help people whose idiopathic pulmonary fibrosis is starting to flare up (worsen) in the early stages. It’s mainly for adults who are not very sick and cannot require intensive breathing support.
This trial tests a new drug, SB17170, for people with IPF. It aims to see if the drug can help slow down lung damage. You may be eligible if you have a confirmed diagnosis of IPF and meet certain lung function criteria.
Hear when a new Idiopathic Pulmonary Fibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.